Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000934 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies
A Phase 1 study of Advanced Solid Tumor and Lymphoma Malignancies, sponsored by Calithera Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 143
- Enrollment target
- 15
- Study locations
NCT02000934 is a Phase 1 study of Advanced Solid Tumor and Lymphoma Malignancies that has completed, run by Calithera Biosciences. The registered enrollment target is 143 participants. The trial reports 15 study locations across 8 states.
The verdict
NCT02000934, a Phase 1 study of Advanced Solid Tumor and Lymphoma Malignancies, has completed, sponsored by Calithera Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 143 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult participants with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The participants population during dose escalation (Part A) will consist of adults previously diagnosed with any form of a solid tumor or lymphoma for which standard, curative, or life-prolonging treatment does not exist or is no longer effective. This first-in-human (FIH) study will include 5 dose expansion cohorts in refractory and/or relapsed Chronic Lymphocytic Leukemia (CLL), Diffuse Large B Cell Lymphoma (DLBCL), indolent Non Hodgkin Lymphoma (iNHL), Mantle Cell Lymphoma (MCL), Post Transplant Lymphoproliferative Disorder (PTLD) (Part B) following completion of dose escalation (Part A).
Conditions Studied
Interventions
- DRUG TAK-659
Study Locations (15)
Other
- Azienda Ospedaliera Papa Giovanni XXIII - Bergamo
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Bologna
- Ospedale San Raffaele U.O. di Ematologia e Trapianto di midollo osseo - Milan
- Azienda Ospedaliera Universitaria Policlinico Tor Vergata - Roma
- Hospital Universitari Vall d'Hebron - Barcelona
- Avda. Reyes Catolicos, 2 - Madrid
- Centro Integral Oncologico Clara Campal - Madrid
Texas
- The Methodist Hospital Research Institute - Houston
- University of Texas Health Science Center at San Antonio - San Antonio
Florida
- Florida Cancer Specialists, Sarasota FL - Sarasota
Illinois
- Northwestern University - Chicago
Tennessee
- SCRI - Nashville
Greater London
- University College London Hospitals - London
Greater Manchester
- The Christie - Manchester
Surrey
- Royal Marsden Hospital - Sutton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2013-12-31 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02000934
The ClinicalTrials.gov registry entry for NCT02000934 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumor and Lymphoma Malignancies appearing as the primary indexed condition, and to 1 intervention - of which TAK-659 is the first listed.
NCT02000934 reports 15 study locations spanning 8 distinct geographic areas - top geographies include Other, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT02000934 about?
NCT02000934 is a clinical study titled "A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies". This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult participants with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The participants population during dose escalation (Part A) will consist of adu...
What is the current status of trial NCT02000934?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 143 participants. The study started on 2013-12-31. Estimated completion is 2021-06-29.
What conditions does trial NCT02000934 study?
This clinical trial studies the following conditions: Advanced Solid Tumor and Lymphoma Malignancies.
What interventions are being tested in trial NCT02000934?
The interventions under investigation include: TAK-659 (DRUG).
Who is sponsoring clinical trial NCT02000934?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02000934 being conducted?
This trial has 15 study locations across Florida, Illinois, Tennessee, Texas, Greater London. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.